1Higgs DR,Engel JD,Stamatoyannopoulos G. Thalassaemia[J].{H}LANCET,2012.373-383.
2Schechter AN. Hemoglobin research and the origins of molecular medicine[J].{H}Blood,2008.3927-3938.
3Tsiftsoglou AS,Vizirianakis IS,Strouboulis J. Erythropoiesis:model systems,molecular regulators,and developmental programs[J].{H}IUBMB LIFE,2009.800-830.
4Williamson D. The unstable haemoglobins[J].{H}Blood Reviews,1993.146-163.
5Gordeuk VR,Stockton DW,Prchal JT. Congenital polycythemias/erythrocytoses[J].{H}HAEMATOLOGICA,2005.109-116.
6Skold A,Cosco DL,Klein R. Methemoglobinemia:pathogenesis,diagnosis,and management[J].{H}Southern Medical Journal,2011.757-761.
7Cunningham MJ. Update on thalassemia:clinical care and complications[J].{H}Pediatric Clinics of North America,2008.447-460.
8Masera N,Tavecchia L,Capra M. Optimal response to thalidomide in a patient with thalassaemia major resistant to conventional therapy[J].Blood Transfus,2010.63-65.
9Testa U. Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies[J].{H}Annals of Hematology,2009.505-528.
10Woon K Y,Kim S,Geun K C. The distinctive roles of erythroid specific activator GATA-1 and NF-E2 in transcription of the human fetal gamma-globin genes[J].{H}Nucleic Acids Research,2011.6944-6955.
